Following Pfizer and Moderna’s request for liability compensation, sources indicate that Covishield-Serum maker’s Institute, India (SII). It has reportedly been told to the government that all vaccine makers, whether Indian or foreign, should be provided with the same protection.
Not just Serum Institute of India (SII), all the vaccine companies should get indemnity protection against liabilities if foreign companies are granted it,” Serum sources said today.
Covishield – the Indian name for Oxford-shot AstraZeneca’s – is being produced at Serum Institute and participating in trials of three new anti-covidic vaccines.
Advanced testing is under way for Covovax in conjunction with the Novovax pharmaceutical company. The phase 1/2 studies in the UK involve Codagenix, a single-dose nasal vaccine. The third, SpyBiotech, is a new particle-like virus vaccine, also being tested.
To date, there has been no compensation or protection for serious side effects from the manufacturers or from legal action.
This is a key requirement for India supply by foreign vaccine manufacturers Pfizer and Moderna.
Sources from the Health Ministry stated yesterday that other countries granted the concession and “no trouble” granted any claims associated with the use of COVID-19 vaccinations in the health ministry.
“It is expected that they will be granted indemnity against legal proceedings along the lines of what has been allowed in other countries for Pfizer and Moderna,” they added.
Countries such as the U.S. have paid these companies compensation for the chance that their vaccines may cause anything wrong. If there are any adverse effects of the shot they cannot be sued for compensation.
Sources say that a sovereign compensation demand by Pfizer is a tough call, which has not been secured so far by any other vaccine fabricator.
